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Objective. In October 2004, rofecoxib was removed from the world market because of an increased risk of myocardial
infarction. The aim of the present study was to compare the trend of nonsteroidal antiinﬂammatory drug (NSAID) use and
other analgesics in osteoarthritis (OA) treatment before and after rofecoxib withdrawal in Italian general practice.
Methods. From the Caserta-1 Local Health Service database, 97 general practitioners were recruited. Prevalence and
incidence of use of any study drug were calculated within 1 year before and after rofecoxib withdrawal.
Results. One-year prevalence of nonselective and preferential NSAID use did not change after rofecoxib withdrawal,
whereas coxib use fell from 4.4% (95% conﬁdence interval [95% CI] 4.2–4.5%) in the period before rofecoxib withdrawal
(period I) to 1.6% (95% CI 1.5–1.7%) in the period after withdrawal (period II). Weak opioids were used in no more than
0.4% (95% CI 0.3–0.5%) in period II, after their introduction to reimbursement in December 2004. Also, 1-year incidence
of coxib decreased from 31.3 per 1,000 (95% CI 30.2–32.4%) in period I to 8.7 per 1,000 (95% CI 8.1–9.2%) in period II.
The disappearance of rofecoxib was associated with replacement drugs such as newly marketed dexibuprofen and
aceclofenac, whereas nimesulide use coincidentally decreased.
Conclusion. Rofecoxib withdrawal has markedly changed the prescribing pattern of drugs that are used in OA-related
pain treatment, with a striking decrease of coxib use in Italian general practice. Education strategies addressed to health
professionals should be planned to improve the management of pain treatment, particularly in degenerative joint
diseases.
INTRODUCTION
Osteoarthritis (OA) is widely known as the most frequent
musculoskeletal disorder, mainly occurring in the elderly
(1,2), with a radiographic prevalence of nearly 70% in
persons over age 65 (1). Disease burden is related to pain
occurrence, frequently leading to functional disability
ranging from slight limitation of movements to severe im-
pairment of normal daily living activities (3,4). Therefore,
pain relief plays an important role in the treatment of OA.
Although acetaminophen is indicated as ﬁrst-line therapy
for controlling pain in persons with OA (5–7), nonsteroi-
dal antiinﬂammatory drugs (NSAIDs) are the most effec-
tive medications (8,9). In the late 1980s, the increasing
evidence of serious gastrointestinal (GI) adverse events
(e.g., GI perforation, ulceration, and bleeding) led to a
progressive decline in NSAID use for OA treatment, espe-
cially among elderly patients, while acetaminophen use
did not increase as expected (10). Starting in 1998 (11), the
marketing of a new class of NSAIDs with a low GI toxicity
risk, the selective cyclooxygenase 2 (COX-2) inhibitors
(coxibs), mainly celecoxib and rofecoxib (12–14), changed
the prescribing pattern of painkillers in OA. Indeed, coxibs
were suggested as ﬁrst-line therapy in the treatment of
OA-related pain in patients at high risk of GI bleeding
(15,16). In October 2004, however, rofecoxib was with-
drawn from the market because of evidence of an in-
creased risk of myocardial infarction (17). In light of these
events, the goal of our study was to compare the trend in
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use of different NSAIDs and other analgesic drugs for the
treatment of OA-related pain before and after rofecoxib
withdrawal in a general practice in southern Italy.
Because NSAIDs are a major cause of serious adverse
drug reactions and of regulatory interventions, and taking
into account the high prevalence of OA, we think that our
report may be important to obtain information about the
pattern of prescribing painkillers by general practitioners
(GPs) after a sudden and unexpected withdrawal of a drug
from the market.
PATIENTS AND METHODS
Data source. Data were extracted from the Arianna da-
tabase during the period September 30, 2003 to September
30, 2005. This database, set up by the Health Service
Agency of Caserta city in the year 2000, currently contains
information about a population of almost 300,000 individ-
uals living in the catchment area of Caserta who are regis-
tered with 225 (73.7%) of 305 GPs practicing in the same
area. Participating GPs record data during their daily clin-
ical practice using dedicated software and send monthly
complete and anonymous data concerning their patients to
the Arianna database. Information collected includes pa-
tient demographics and drug prescriptions coded accord-
ing to the Anatomical Therapeutic Chemical (ATC) classi-
ﬁcation system and linked to medical diagnoses coded by
the International Classiﬁcation of Diseases, Ninth Revision
(ICD-9).
All participating GPs received extensive training in data
collection techniques. Routine quality checks included
analysis of several parameters such as missing patient
codes, number of daily ﬁlled prescriptions, proportion of
prescriptions correctly linked to medical diagnoses, and
monthly continuity of data submission. Any variation
within deﬁned ranges was investigated and back submit-
ted to each participating GP in order to receive immediate
feedback about data quality and completeness. GPs failing
to meet these standard quality criteria were not retained
within the project, according to basic standards in the
conduct of pharmacoepidemiologic studies (18). So far,
the Arianna database has been shown to provide accurate
and reliable information about drug utilization in general
practice (19–21).
Educational intervention for GPs. Starting in 2001, GPs
enrolled in the study were well trained concerning the
guidelines for OA diagnosis (22,23) and treatment (5–7),
thanks to a continuous medical educational program of
interactive teaching intervention and decisional algo-
rithms presentation (24–27) by 2 well-experienced rheu-
matologists (RC and LC).
Study population. Overall, 97 GPs who continuously
sent data to the Arianna database during the period Sep-
tember 30, 2003 to September 30, 2005 were selected for
this investigation. Among 142,346 individuals age 25
years who were registered with these GPs, patients who
received at least 1 prescription for the treatment of OA-
related pain (ICD-9 code 715) during the observation years
were identiﬁed. Patients were included in the study irre-
spective of whether pharmacologic treatment was initiated
by GPs or by specialists working in the public or private
sector. Indeed, in Italy, outpatients being treated by spe-
cialists receive medicines free of charge only if prescribed
by a GP.
The following drug cohorts were identiﬁed: 1) NSAIDs,
divided (based on afﬁnity to cox enzyme isoforms) into
COX-2 preferential (nabumetone [ATC code M01AX01],
meloxicam [ATC code M01AC06], and nimesulide [ATC
code M01AX17]), coxib (celecoxib [ATC code M01AH01],
rofecoxib [ATC code M01AH02], valdecoxib [ATC code
M01AH03], and etoricoxib [ATC code M01AH05]), and
nonselective (NS) NSAIDs (all M01A, except for coxib and
COX-2 preferential), and 2) weak opioids (ATC codes
N02AE, N02AX) that are reimbursed by the Italian Na-
tional Health System (NHS) since December 2004. Acetyl-
salicylic acid is not reimbursed when prescribed as an
analgesic drug, and parecoxib was never marketed in Italy;
therefore, these medications were not included in the ana-
lysis. Acetaminophen is also not reimbursed by the Italian
NHS. At the end of the study, however, all GPs enrolled in
this investigation completed a questionnaire that asked
them to indicate whether acetaminophen utilization for
OA-related pain was increased or decreased after rofecoxib
withdrawal. After identiﬁcation of users of study drugs,
information about patient demographics and drug pre-
scriptions recorded during the study period was retrieved
using the Arianna database. Furthermore, utilization of
different study drugs was evaluated before and after rofe-
coxib withdrawal, according to presence of concurrent GI
diseases (ICD-9 codes 530–537, 578) and coronary heart
disease (ICD-9 codes 410–414).
Prevalence and incidence of use. For each 1-year pe-
riod, the prevalence of the study drugs was calculated as
the number of study drug users divided by the number of
patients alive and registered in the GPs’ lists. Within each
1-year period, we deﬁned a new user as a patient receiving
a ﬁrst prescription for OA-related pain treatment without
any prescription in the previous year. Before and after
rofecoxib withdrawal, the cumulative incidence rate was
measured as the number of new users divided by the
number of patients free from study drug use in the previ-
ous year. Regarding opioid prescriptions, our data were
limited to the period subsequent to rofecoxib withdrawal,
because these drugs were not previously reimbursed and
therefore were not registered in the database. Both preva-
lence and incidence were expressed as rates per 100 or per
1,000 inhabitants, together with 95% conﬁdence intervals
(95% CIs).
Statistical analysis. Chi-square test for categorical vari-
ables and Student’s t-test for continuous variables, with a
signiﬁcance level of P  0.05, were used for assessing the
differences among users of various study drug types
within 2 years of observation. Statistical analyses were
performed using STATA 6.0 (StataCorp, College Station,
TX).
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RESULTS
Prevalence of study drug use before and after rofecoxib
withdrawal. Overall, there was a minor but signiﬁcant
(P  0.05) decrease in the prescribing of OA symptomatic
drugs from 21.3 (95% CI 20.9–21.5) to 20.5 (95% CI 20.2–
20.8) per 100 inhabitants in the period before (period I)
and after (period II) rofecoxib withdrawal, respectively
(Figure 1). In particular, such a decrease was more clearly
shown (P  0.05) in patients age 65 years (period I:
52.3%, 95% CI 51.3–53.2; period II: 48.6%, 95% CI 47.6–
49.4).
Regarding different study drugs, NS NSAID use resulted
in a slight increase in prevalence after rofecoxib with-
drawal from 12.1% (95% CI 11.8–12.2) in period I to
12.7% (95% CI 12.4–12.8) in period II (Figure 2). In con-
trast, the prevalence of COX-2 preferential use remained
rather stable between the study years (period I: 11.8%,
95% CI 11.5–11.9; period II: 11.5%, 95% CI 11.2–11.6).
The prevalence of coxib use fell from 4.4% (95% CI 4.2–
4.5) in period I to 1.6% (95% CI 1.5–1.7) in period II. Weak
opioids, reimbursed by the Italian NHS since December
2004, were used in 0.4% (95% CI 0.3–0.5%) of patients
with OA after rofecoxib withdrawal.
Looking speciﬁcally at coxibs, the prevalence of use per
1,000 inhabitants decreased for both rofecoxib (period I:
20.4, 95% CI 19.5–21.2; period II: 0.2, 95% CI 0.1–0.3) and
celecoxib (period I: 21.5, 95% CI 20.5–22.4; period II: 9.0,
95% CI 8.3–9.5) (data not shown). Only use of etoricoxib
did not change during the 2 observation years (period I:
7.2, 95% CI 6.6–7.7; period II: 7.1, 95% CI 6.5–7.6). Valde-
coxib, marketed in June 2004 and withdrawn in April
2005, was poorly used during the study period compared
with other coxibs (0.9, 95% CI 0.7–1.0).
Figure 3 shows the prevalence of use, per 1,000 inhab-
itants, of medications accounting for 90% of total pain-
killer prescriptions in patients with OA. Almost 50% of
patients treated for OA-related pain received at least 1
prescription of nimesulide during the study period. Prev-
alence of nimesulide use was 2 times higher than that of
diclofenac (the second most used medication) in both
years, although its prevalence of use slightly decreased
after the rofecoxib withdrawal. The disappearance of rofe-
coxib induced signiﬁcant changes in the prescribing of
different drug classes. Concerning coxibs, a more than
50% reduction in celecoxib use was reported, whereas no
changes in the prescribing of etoricoxib were shown. Re-
garding COX-2 preferential and NS NSAID use, aceclofe-
nac use was 2 times higher in period II (11.3 per 1,000)
compared with period I (6.6 per 1,000), whereas use of
dexibuprofen, marketed in May 2004 in Italy, increased
from 0.2 per 1,000 to 5.1 per 1,000 after rofecoxib removal.
One-year incident use of NSAIDs before and after rofe-
coxib withdrawal. The cumulative incidence of treatment
with NS NSAIDs was 73.6 (95% CI 71.9–75.3) per 1,000
Figure 1. Prevalence of use, per 100 inhabitants, of drugs for
osteoarthritis-related pain, stratiﬁed by age groups and study pe-
riods. Period I (solid bars)  before rofecoxib withdrawal (from
October 1, 2003 to September 30, 2004); period II (open bars) 
after rofecoxib withdrawal (from October 1, 2004 to September 30,
2005). Tot  total.
Figure 2. Prevalence of use, per 100 inhabitants, of different
study drug types, stratiﬁed by study periods. Period I (solid
bars)  before rofecoxib withdrawal (from October 1, 2003 to
September 30, 2004); period II (open bars)  after rofecoxib with-
drawal (from October 1, 2004 to September 30, 2005). NS NSAID
 nonselective nonsteroidal antiinﬂammatory drug; pref.  pref-
erential.
Figure 3. Prevalence of use, per 1,000 inhabitants, of individual
medications stratiﬁed by study periods. Medications accounting
for90% of total drug prescriptions for osteoarthritis-related pain
treatment have been included in the analysis. Period I (solid
bars)  before rofecoxib withdrawal (from October 1, 2003 to
September 30, 2004); period II (open bars)  after rofecoxib with-
drawal (from October 1, 2004 to September 30, 2005).
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inhabitants and 78.7 (95% CI 76.9–80.4) before and after
rofecoxib withdrawal, respectively. Incident use of COX-2
preferentials was unmodiﬁed during the study period:
54.9 per 1,000 inhabitants (95% CI 53.4–56.5). In contrast,
incident use of coxibs strongly decreased from 31.3 per
1,000 (95% CI 30.2–32.4) in period I to 8.7 (95% CI 8.1–
9.2) in period II.
Clinical characteristics of study drug users. Clinical
characteristics of study drug users are described in Table
1. Coxib users were mostly women and were older than
other NSAID users. Moreover, the proportion of coxib
users age 65 years was higher after rofecoxib withdrawal
(66.8%, 95% CI 62.8–70.8) compared with before (63.7%,
95% CI 61.3–66.1).
The proportion of coxib users who were affected by GI
diseases or used antiplatelet agents or proton-pump inhib-
itors (when used as gastroprotective agents) was higher
than users of other NSAIDs, particularly after rofecoxib
withdrawal. In contrast, the proportion of patients with
coronary heart disease was rather similar among users of
all NSAID subgroups, with a slight reduction (not statisti-
cally signiﬁcant) after rofecoxib withdrawal.
DISCUSSION
In the late 1980s, awareness of NSAID-related GI adverse
events led to a decreased use of these medications in older
patients with OA (10). By itself, this fact is not surprising
because elderly persons are at a high risk of NSAID-related
GI toxicity (28–30). When coxibs were introduced into the
drug market, these health issues seemed to be partially
solved (12–14) and NSAID use in the elderly increased
40%, entirely due to COX-2 inhibitors (14). Coxibs, how-
ever, are not completely safe and their marketing surpris-
ingly led to an increased hospitalization rate due to upper
GI hemorrhage in patients age 65 years (14). In contrast,
cardiovascular risks were also reported for rofecoxib (13).
As a consequence, on September 30, 2004, rofecoxib was
withdrawn from the market due to the results of the Ad-
enomatous Polyp Prevention on Vioxx (APPROVe) study
(17), showing that long-term rofecoxib use was related to
higher risk of myocardial infarction compared with pla-
cebo.
Although the initial impact of coxibs on the pharmaco-
logic treatment of patients with OA is well known (31), we
were unaware of the consequences of the withdrawal of
rofecoxib on pain treatment in OA. Indeed, previous drug
utilization studies demonstrated that rofecoxib with-
drawal reduced the prescription of celecoxib (32), also
with a delayed effect (33), and reduced the prescription of
all coxibs (31), whereas an increase in the use of classic
NSAIDs, such as diclofenac, ibuprofen, meloxicam, and
etodolac, has been reported (32). In these articles, how-
ever, despite the amount of data available, no information
was given about the real motivation of coxib and NSAID
prescriptions, and thus it was not possible to speciﬁcally
evaluate the burden of rofecoxib withdrawal on OA treat-
ment.
In our analysis, overall use of painkillers in patients
with OA decreased slightly but signiﬁcantly after rofe-
coxib withdrawal. This decrease occurred particularly in
patients age 65 years and was mainly due to a reduction
in coxib utilization, whereas COX-2 preferential and NS
NSAID use did not signiﬁcantly change.
Because acetaminophen is not reimbursed by the Italian
NHS, our data source did not make it possible to analyze
utilization of acetaminophen. For this reason, at the end of
the study, we administered a speciﬁc and simple question-
naire to GPs about acetaminophen utilization in patients
Table 1. Demographic and clinical characteristics of NSAID users due to osteoarthritis before and after rofecoxib withdrawal*
Coxib Nonselective NSAID Selective NSAID
Before
(n  4,320)
After
(n  1,630)
Before
(n  11,762)
After
(n  12,693)
Before
(n  11,462)
After
(n  11,500)
Age, mean  SD years 67.5  11.5 68.3  11.3 63.7  13.3 63.8  12.9 66.0  12.0 66.0  11.5
65 1,568 (36.3) 542 (33.2) 5,657 (48.1) 6,154 (48.5) 4,832 (42.2) 4,917 (42.7)
65 2,752 (63.7) 1,088 (66.8) 6,105 (51.9) 6,539 (51.5) 6,630 (57.8) 6,583 (57.3)
Sex
Male 1,335 (30.9) 445 (27.3) 4,388 (38.3) 4,661 (36.7) 4,321 (37.7) 4,310 (37.5)
Female 2,985 (69.1) 1,185 (72.7) 7,374 (62.7) 8,032 (63.3) 7,141 (62.3) 7,190 (62.5)
Concurrent disease
GI diseases† 711 (16.4) 309 (18.9) 1,653 (14.0) 1,857 (14.6) 1,461 (12.7) 1,578 (13.7)
CHD‡ 210 (4.8) 74 (4.5) 504 (4.3) 488 (3.8) 571 (5.0) 547 (4.7)
Concomitant drugs
Antiplatelet agents 976 (22.5) 363 (22.3) 2,147 (18.2) 2,432 (19.2) 2,304 (20.1) 2,403 (20.9)
Anticoagulants 53 (1.2) 10 (0.6) 106 (0.9) 118 (0.9) 113 (1.0) 111 (1.0)
PPI due to
Gastroprotection 200 (4.6) 84 (5.1) 428 (3.6) 350 (2.7) 331 (2.9) 270 (2.3)
Other GI diseases 838 (19.3) 280 (17.2) 1,787 (15.2) 1,679 (13.2) 1,513 (13.2) 1,378 (12.0)
* Values are the number (percentage) unless otherwise indicated. NSAID nonsteroidal antiinﬂammatory drug; GI gastrointestinal; CHD coronary
heart disease; PPI  proton-pump inhibitor.
† Diseases of the esophagus, gastric and duodenal ulcer, gastritis and duodenitis, functional disorders of the stomach and duodenum, and GI bleeding.
‡ Myocardial infarction, angina pectoris, and other coronary heart disease. Both concomitant diseases and medications were evaluated at the ﬁrst
prescription of drugs for osteoarthritis within each study year.
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with OA. GPs indicated, in general, a low use of such an
analgesic in patients with OA, without any variation after
rofecoxib withdrawal. In line with a previous survey en-
rolling a large number of Italian GPs (34), our study also
suggests an underutilization of acetaminophen in OA-re-
lated pain treatment after rofecoxib withdrawal. This ﬁnd-
ing might be partly explained by the fact that acetamino-
phen is in charge of citizens.
Furthermore, the high prevalence of NSAID use can be
related to the analgesic and antiphlogistic properties of
NSAIDs; in fact, inﬂammation is one of the main determi-
nants of pain and disease progression in OA (31,33). Thus,
a class of drugs with analgesic power that act on inﬂam-
mation may have a very important place in this setting,
and this is in line with OA patients’ preference for NSAIDs
(8,9).
The interpretation of pain treatment in patients with OA
is not univocal. First, pain may now be considered less by
GPs than before rofecoxib withdrawal, as previously de-
scribed by Ausiello and Stafford for traditional NSAIDs.
Second, it is possible to speculate an overtreatment of
OA-related pain by GPs before rofecoxib withdrawal, ac-
cording to the well-established GI safety of coxibs (12–14).
In contrast with previous studies (35,36), in patients age
65 years, we found a lower utilization of coxibs com-
pared with COX-2 preferential and NS NSAIDs both before
and after rofecoxib withdrawal. The strong reduction in
coxib prescriptions after rofecoxib removal, particularly in
older patients, suggests that cardiotoxicity plays a primary
role in changing the prescribing behavior of GPs.
Moreover, prevalence of celecoxib use decreased to less
than half, suggesting that a class effect of coxibs is consid-
ered by GPs. Although data about rofecoxib are undispu-
table, as outlined by the re-analysis of the APPROVe study
(37), celecoxib does not seem to increase the risk of car-
diovascular events at the commonly used dose (38–40),
probably as a result of lower selectivity for COX-2 com-
pared with other coxibs. In contrast, growing evidence
underlines the cardiovascular risk of traditional NSAIDs
such as diclofenac (40,41), naproxen (42), ibuprofen (41),
and other NSAIDs such as nabumetone, meloxicam,
etodolac, and nimesulide (43). Nevertheless, according to
the study ﬁndings, fewer patients affected by coronary
heart disease were treated in all NSAID groups in period II.
Interestingly, celecoxib use decreased more than 50%
after rofecoxib withdrawal, whereas the use of etoricoxib
(marketed in Italy since March 2004) remained unmodi-
ﬁed. The extensive marketing campaign launched by drug
manufacturers to promote new drugs might partly explain
such a peculiar ﬁnding (44).
Concerning coprescription of gastroprotective agents,
our results show a low rate of proton-pump inhibitor treat-
ment in users of traditional NSAIDs (45). In contrast, the
rate of gastroprotection with proton-pump inhibitors in
coxib users was higher than in other NSAID users. This
trend has been previously described for both traditional
NSAIDs (46,47) and coxibs (47). This ﬁnding might be
explained by the channeling effect of coxibs that are more
likely to be prescribed in patients with higher GI risks
compared with other NSAIDs (48).
Finally, we observed a low rate of utilization of weak
opioids, despite their well-deﬁned role in published
guidelines (5–7) and the fact that they became fully reim-
bursed in Italy after December 2004. This evidence might
be related to the concerns about tolerability of weak opi-
oids, which are associated with a high frequency of side
effects such as dry mouth, nausea, and constipation
(49,50).
Overall, our investigation highlights that the adherence
of GPs to published guidelines (5–7) was not satisfactory
and this should be analyzed despite accurate and regular
training.
To our knowledge, this is the ﬁrst drug utilization study
performed in Italy with the aim of evaluating the effect of
rofecoxib withdrawal on pain treatment in patients with
OA in a general practice setting. However, several limita-
tions of the study should be considered. First, diagnoses
were made only by GPs and were not conﬁrmed by a
rheumatologist/orthopedic specialist when drug prescrip-
tion was directly decided by a GP. Second, data on pain
severity requiring drug prescriptions were missing. An-
other limitation was the lack of data on acetaminophen
utilization directly measured in the study population dur-
ing the observation years. However, as previously men-
tioned, we tried to estimate such a utilization through a
questionnaire that was administered to GPs at the end of
the study. Furthermore, we missed information on self-
treatment and over-the-counter drugs because we used an
outpatient prescription database. Nevertheless, the goal of
the study was to look at the medications that are actually
prescribed by GPs. Finally, data on weak opioid use before
December 2004 were missing because these medications
did not become fully reimbursable until this date and our
data source contained only data on drug prescriptions that
are reimbursed by the NHS. Given that our study reported
a low utilization of weak opioids after rofecoxib with-
drawal, we might speculate that the use of these medica-
tions in the previous period was similar or even lower.
In conclusion, rofecoxib withdrawal led to a reduction
of coxib use in patients with OA despite the fact that
utilization of COX-2 preferentials, NS NSAIDs, and anal-
gesic opioids remained stable. Even though an educational
program was performed during the study period, our ﬁnd-
ings suggest that GPs tend not to be adherent to recom-
mendations of treatment guidelines for OA-related pain, or
recommendations regarding gastroprotection in classic
NSAID and coxib users.
ACKNOWLEDGMENTS
We would like to thank all of the following general prac-
titioners from Caserta-1 Local Health Unit, who actively
participated in this investigation by continuously sending
data to the Arianna database in the years 2003–2005: Maria
Carmela Abussi, Maria Petronilla Addeo, Ciro Natale Af-
ﬁnita, Luigi Ambrosio, Antonio Anastasio, Maria Clotilde
Apperti, Domenico Barbato, Diana Basile, Guido Bernardi,
Giuseppe Bernardo, Antonio Betti, Nicola Buono, Anna
Campanile, Silvestro Canzano, Maria Concetta Caradonna,
Marianna Ceniccola, Augusto Cesare, Maria Teresa
Chirico, Ferdinando Cicala, Angelo Ciofﬁ, Carmine Cor-
bisiero, Alessandro Correra, Pasquale Corvino, Attilio
572 Alacqua et al
Costarella, Angelo Crescente, Nobile D’acunzo, Roberto
D’Andrea, Rosa D’argenzio, Francesco De Lucia, Franco
Pierino De Lucia, Ornella De Matteis, Marcantonio De
Rosa, Patrizia De Rosa, Giustino De Sire, Andrea Del
Buono, Massimo Del Forno, Renato Del Forno, Giacinto
Della Rocca, Annamaria Dell’aquila, Domenico Delle
Curti, Angelo Desiato, Michele Di Domenico, Marcellino
Di Muccio, Giuseppe Diodati, Gianfranco Failli, Umberto
Renato Fasulo, Carlo Eugenio Ferrucci, Francesco Fer-
rucci, Antonio Gaglione, Giovanni Alfonso Giarrusso, Ar-
turo Giglioﬁorito, Agostino Greco, Fernando Iannelli, En-
rico Iorio, Maurizio Iuliano, Michele La Vedova, Gennaro
Lauritano, Renato Leone, Giuseppe Letizia, Maria Letizia,
Innocenzo Lombardi, Antonio Mancino, Antonio Marino,
Francesco Carlo Marino, Angelo Marrocco, Giorgio Mas-
sara, Bruno Migliozzi, Baldassarre Mirra, Salvatore Mor-
etti, Sergio Nunziata, Andrea Pascarella, Domenico Pas-
carella, Silvio Pascarella, Vincenzo Perone, Manfredo
Perrino, M. Giovanna Pontillo, Aldo Porciello, Giovanni
Porﬁdia, Giacomo Lupo Pulcino, Luigi Ragucci, Benedetto
Ricciardi, Michele Roberti, Giovanni Russo, Saverio
Russo, Clemente Sagnelli, Girolamo Salzillo, Lucia Carla
Savignano, Fausto Scalzitti, Antonio Sibillo, Mauro Sicig-
nano, Rodolfo Aniello Sirignano, Giacomo Tartaglione,
Luigi Trombetta, Massimo Visco, Giacomo Vozza,
Francesco Zaccaria, Giovanni Zeppetelli.
AUTHOR CONTRIBUTIONS
Dr. Alacqua had full access to all of the data in the study and
takes responsibility for the integrity of the data and the accuracy
of the data analysis.
Study design. Alacqua, Triﬁro`, Caputi.
Acquisition of data. Galdo, Caputi, Arcoraci.
Analysis and interpretation of data. Alacqua, Triﬁro`, Cavagna,
Caporali, Montecucco, Moretti, Galdo, Arcoraci.
Manuscript preparation. Alacqua, Triﬁro`, Cavagna, Caporali,
Montecucco, Moretti, Tari.
Statistical analysis. Tari, Arcoraci.
REFERENCES
1. Altman RD. The syndrome of osteoarthritis. J Rheumatol
1997;24:766–7.
2. Loeser RF, Shakoor N. Aging or osteoarthritis: which is the
problem? Rheum Dis Clin North Am 2003;29:653–73.
3. Maurer K. Basic data on arthritis knee, hip and sacroiliac
joints in adult ages 25-74 years. Vital Health Stat 11 1979;213:
1–31.
4. World Health Organisation and the Bone and Joint Decade.
2001. URL: http://www.boneandjointdecade.org/.
5. Pendleton A, Arden N, Dougados M, Doherty M, Bannwarth
B, Bijlsma JW, et al. EULAR recommendations for the man-
agement of knee osteoarthritis: report of a task force of the
Standing Committee for International Clinical Studies Includ-
ing Therapeutic Trials (ESCISIT). Ann Rheum Dis 2000;59:
936–44.
6. American College of Rheumatology Subcommittee on Osteo-
arthritis Guidelines. Recommendations for the medical man-
agement of osteoarthritis of the hip and knee: 2000 update.
Arthritis Rheum 2000;43:1905–15.
7. Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J,
Gunther KP, et al, and the EULAR Standing Committee for
International Clinical Studies Including Therapeutics (ES-
CISIT). EULAR evidence based recommendations for the
management of hip osteoarthritis: report of a task force of the
EULAR Standing Committee for International Clinical Studies
Including Therapeutics (ESCISIT). Ann Rheum Dis 2005;64:
669–81.
8. Pincus T, Swearingen C, Cummins P, Callahan LF. Preference
for nonsteroidal antiinﬂammatory drugs versus acetamino-
phen and concomitant use of both types of drugs in patients
with osteoarthritis. J Rheumatol 2000;27:1020–7.
9. Towheed TE, Judd MJ, Hochberg MC, Wells G. Acetamino-
phen for osteoarthritis. Cochrane Database Syst Rev 2003;2:
CD004257.
10. Ausiello JC, Stafford RS. Trends in medication use for osteo-
arthritis treatment. J Rheumatol 2002;29:999–1005.
11. Mamdani M, Juurlink DN, Kopp A, Naglie G, Austin PC,
Laupacis A. Gastrointestinal bleeding after the introduction of
COX 2 inhibitors: ecological study. BMJ 2004;328:1415–6.
12. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T,
Whelton A, et al. Gastrointestinal toxicity with celecoxib vs
nonsteroidal anti-inﬂammatory drugs for osteoarthritis and
rheumatoid arthritis: the CLASS study. A randomized con-
trolled trial: Celecoxib Long-term Arthritis Safety Study.
JAMA 2000;284:1247–55.
13. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R,
Davis B, et al, and the VIGOR Study Group. Comparison of
upper gastrointestinal toxicity of rofecoxib and naproxen in
patients with rheumatoid arthritis. N Engl J Med 2000;343:
1520–8.
14. Mamdani M, Rochon PA, Juurlink DN, Kopp A, Anderson
GM, Naglie G, et al. Observational study of upper gastrointes-
tinal haemorrhage in elderly patients given selective cyclo-
oxygenase-2 inhibitors or conventional non-steroidal anti-
inﬂammatory drugs. BMJ 2002;325:624–9.
15. Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL,
Quan H, et al. Adverse upper gastrointestinal effects of rofe-
coxib compared with NSAIDs. JAMA 1999;282:1929–33.
16. Goldstein JL, Silverstein FE, Agrawal NM, Hubbard RC, Kai-
ser J, Maurath CJ, et al. Reduced risk of upper gastrointestinal
ulcer complications with celecoxib, a novel COX-2 inhibitor.
Am J Gastroenterol 2000;95:1681–90.
17. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B,
Horgan K, et al, and the Adenomatous Polyp Prevention on
Vioxx (APPROVe) Trial Investigators. Cardiovascular events
associated with rofecoxib in a colorectal adenoma chemopre-
vention trial [published erratum appears in N Engl J Med
2006;355:221]. N Engl J Med 2005;352:1092–102.
18. Lawrenson R, Williams T, Farmer R. Clinical information for
research: the use of general practice databases. J Public Health
Med 1999;21:299–304.
19. Piacentini N, Triﬁro G, Tari M, Moretti S, Arcoraci V, and the
UVEC group. Statin-macrolide interaction risk: a population-
based study throughout a general practice database. Eur J Clin
Pharmacol 2005;61:615–20.
20. Triﬁro G, Corrao S, Alacqua M, Moretti S, Tari M, Caputi AP,
et al. Interaction risk with proton pump inhibitors in general
practice: signiﬁcant disagreement between different drug-re-
lated information sources. Br J Clin Pharmacol 2006;62:582–
90.
21. Triﬁro G, Barbui C, Spina E, Moretti S, Tari M, Alacqua M, et
al. Antidepressant drugs: prevalence, incidence and indica-
tion of use in general practice of Southern Italy during the
years 2003-2004. Pharmacoepidemiol Drug Saf 2007;16:
552–9.
22. Altman R, Alarcon G, Appelrouth D, Bloch D, Borenstein D,
Brandt K, et al. The American College of Rheumatology cri-
teria for the classiﬁcation and reporting of osteoarthritis of the
hand. Arthritis Rheum 1990;33:1601–10.
23. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et
al. Development of criteria for the classiﬁcation and reporting
of osteoarthritis: classiﬁcation of osteoarthritis of the knee.
Arthritis Rheum 1986;29:1039–49.
24. Davis D, O’Brien MA, Freemantle N, Wolf FM, Mazmanian P,
Taylor-Vaisey A. Impact of formal continuing medical
education: do conferences, workshops, rounds, and other tra-
ditional continuing education activities change physician be-
havior or health care outcomes? JAMA 1999;282:867–74.
Effect of Rofecoxib Withdrawal on OA 573
25. Mazmanian PE, Davis DA. Continuing medical education and
the physician as a learner: guide to the evidence. JAMA 2002;
288:1057–60.
26. Hayward RS, Guyatt GH, Moore KA, McKibbon A, Carter AO.
Canadian physicians’ attitudes about and preferences regard-
ing clinical practice guidelines. CMAJ 1997;156:1715–23.
27. Rahme E, Choquette D, Beaulieu M, Bessette L, Joseph L,
Toubouti Y, et al. Impact of a general practitioner educational
intervention on osteoarthritis treatment in an elderly popula-
tion. Am J Med 2005;118:1262–70.
28. Buchanan WW. Implications of NSAID therapy in elderly
patients. J Rheumatol 1990;20:29–32.
29. Weinblatt ME. Nonsteroidal anti-inﬂammatory drug toxicity:
increased risk in the elderly. Scand J Rheumatol Suppl 1991;
91:9–17.
30. Willett LR, Carson JL, Strom BL. Epidemiology of gastrointes-
tinal damage associated with nonsteroidal anti-inﬂammatory
drugs. Drug Saf 1994;10:170–81.
31. Thiebaud P, Patel BV, Nichol MB. Impact of rofecoxib with-
drawal on cyclooxygenase-2 utilization among patients with
and without cardiovascular risk. Value Health 2006;9:361–8.
32. Usher C, Bennett K, Teeling M, Feely J. Characterizing new
users of NSAIDs before and after rofecoxib withdrawal. Br J
Clin Pharmacol 2007;63:494–7.
33. Williams D, Singh M, Hind C. The effect of the withdrawal of
rofecoxib on prescribing patterns of COX-2 inhibitors in Scot-
land. Br J Clin Pharmacol 2006;62:366–8.
34. Scarpa R, Sarzi-Puttini P, Cimmino MA, Caporali R, Parazzini
F, Zaninelli A, et al. Analysis of pharmacologic and non
pharmacologic prescription patterns of general practitioners
and specialists in the AMICA study. Semin Arthritis Rheum
2005;35(1 Suppl 1):24–30.
35. Price-Forbes AN, Callaghan R, Allen ME, Rowe IF, on behalf
of the West Midlands Rheumatology Services and Training
Committee. A regional audit of the use of COX-2 selective
non-steroidal anti-inﬂammatory drugs (NSAIDs) in rheuma-
tology clinics in theWest Midlands, in relation to NICE guide-
lines. Rheumatology (Oxford) 2005;44:921–44.
36. Sarzi-Puttini P, Cimmino M, Scarpa R, Caporali R, Parazzini
F, Zaninelli A, et al. Do physicians treat symptomatic osteo-
arthritis patients properly? Results of the AMICA experience.
Semin Arthritis Rheum 2005;35(1 Suppl 1):38–42.
37. Lagako SW. Time-to-event analyses for long-term treatments:
the APPROVe trial. N Engl J Med 2006;355:113–7.
38. Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, et al.
Celecoxib for the prevention of colorectal adenomatous pol-
yps. N Engl J Med 2006;355:885–95.
39. White WB, West CR, Borer JS, Gorelik PB, Lavange L, Pan SX,
et al. Risk of cardiovascular events in patients receiving
celecoxib: a meta-analysis of randomized clinical trials. Am J
Cardiol 2007;99:91–8.
40. McGettigan P, Henry D. Cardiovascular risk and inhibition of
cyclooxygenase: a systematic review of the observational
studies of selective and non-selective inhibitors of cyclooxy-
genase 2. JAMA 2006;296:1633–44.
41. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in
patients taking cyclo-oxygenase inhibitors or conventional
non-steroidal anti-inﬂammatory drugs: population based
nested case-control analysis. BMJ 2005;330:1366–72.
42. ADAPT Research Group. Cardiovascular and cerebrovascular
events in the randomized, controlled Alzheimer’s Disease
Anti-Inﬂammatory Prevention Trial (ADAPT). PLoS Clin Tri-
als 2006;1:e33.
43. Helin-Salmivaara A, Virtanen A, Vesalainen R, Gronroos JM,
Klaukka T, Idanpaan-Heikkila JE, et al. NSAID use and the
risk of hospitalization for ﬁrst myocardial infarction in the
general population: a nationwide case-control study from Fin-
land. Eur Heart J 2006;27:1657–63.
44. Kozyrskyj A, Raymond C, Racher A. Characterizing early pre-
scribers of newly marketed drugs in Canada: a population-
based study. Eur J Clin Pharmacol 2007;63:597–604.
45. Smalley W, Stein CM, Arbogast PG, Eisen G, Ray WA, Grifﬁn
M. Underutilization of gastroprotective measures in patients
receiving nonsteroidal antiinﬂammatory drugs. Arthritis
Rheum 2002;46:2195–200.
46. Micklewright R, Lane S, Linley W, McQuade C, Thompson F,
Maskrey N. Review article: NSAIDs, gastroprotection and cy-
clo-oxygenase-II-selective inhibitors. Aliment Pharmacol
Ther 2003;17:321–32.
47. Caporali R, Cimmino MA, Sarzi-Puttini P, Scarpa R, Parazzini
F, Zaninelli A, et al. Comorbid conditions in the AMICA
study patients: effects on the quality of life and drug prescrip-
tions by general practitioners and specialists. Semin Arthritis
Rheum 2005;35:31–7.
48. Mosis G, Stijnen T, Castellsague J, Dieleman JP, van der Lei J,
Stricker BH, et al. Channeling and prevalence of cardiovascu-
lar contraindications in users of cyclooxygenase 2 selective
nonsteroidal antiinﬂammatory drugs. Arthritis Rheum 2006;
55:537–42.
49. Large RG, Schug SA. Opioids for chronic pain of non-malig-
nant origin: caring or crippling? Health Care Anal 1995;3:5–
11.
50. Moore RA, McQuay HJ. Prevalence of opioid adverse events
in chronic non-malignant pain: systematic review of random-
ised trials of oral opioids. Arthritis Res Ther 2005;7:R1046–
51.
574 Alacqua et al
